Medical Licensing (MD/DO) · Independent exam preparation
Transplant Hepatology Certification Examination Study Guide
Practise transplant referral, portal-hypertension treatment, donor assessment and graft-complication decisions across the Fall 2026 ABIM certification blueprint.
By CertMedbry · Updated 15 October 2026
Practise recognizing urgent transplant indications, treating decompensated liver disease, assessing donor risk and distinguishing causes of graft dysfunction. These 60 selected concepts emphasize mechanisms and clinical decisions across all five domains of the January 2026 initial certification blueprint, applicable beginning Fall 2026. The official expanded outline defines the full examination scope; this selective guide provides a focused foundation rather than exhaustive coverage.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification pathway does this guide address?
The guide follows the Transplant Hepatology initial Certification Examination, identified by ABIM as CERT. ABIM administers the jointly developed ABIM/ABP program. ABIM gastroenterology certification is an eligibility prerequisite for the ABIM pathway, not the examination covered here. Maintenance assessments, gastroenterology assessments and general medical licensure examinations have different purposes and should not be substituted for this blueprint.
ABIM Transplant Hepatology Certification Policies · ABIM Assessment Blueprints
Which blueprint and effective date apply?
The January 2026 Transplant Hepatology certification blueprint states that its content-selection priorities apply beginning with the Fall 2026 Certification Examination. The expanded CERT outline supplies the detailed subtopics and relevance classifications. HIGH indicates very likely assessment content, MEDIUM indicates moderately likely content, and LOW topic-task combinations are excluded under this blueprint.
Transplant Hepatology Certification Blueprint — January 2026 · Transplant Hepatology Certification Examination — Expanded Blueprint · ABIM Expanded Blueprints
How is the examination content weighted?
The clinical-domain targets are Advanced Hepatology and Pretransplant 55%, Peritransplant 14%, Post-transplant 20%, Transplant Immunology 6%, and Ethics and Regulatory Issues 5%. Physician-task targets are diagnosis/testing 30%, treatment/care decisions 45%, risk assessment/prognosis/epidemiology 18%, and pathophysiology/basic science 7%. These are two classifications of the same examination content and should not be added together.
Transplant Hepatology Certification Blueprint — January 2026 · Transplant Hepatology Certification Examination — Expanded Blueprint
What are the question count, duration, breaks and delivery arrangements?
ABIM schedules approximately 10 hours overall, with four sessions of up to two hours and up to 60 questions each. This permits a maximum of 240 questions; it does not establish a verified scored/pretest split. There are 100 total minutes of break time shared across three breaks, not 100 minutes per break. Delivery is computer-based at Pearson VUE testing centers, with appointments scheduled through ABIM's Physician Portal and Pearson VUE. Allow for registration, instructions and the optional tutorial. See [ABIM's current CERT examination information](https://www.abim.org/certification/becoming-certified-in-a-subspecialty/register-prepare-for-and-take-your-exam/transplant-hepatology/).
What question styles and clinical media are documented?
ABIM describes single-best-answer multiple-choice questions, predominantly patient-based clinical scenarios. Clinical information may include photographs, radiographs, CT, MRI, photomicrographs, tables, pedigree charts, nomograms and other relevant media. These materials use independent four-option, single-best-answer drills and do not predict examination performance.
Transplant Hepatology Certification Blueprint — January 2026
How closely do these learning materials follow the domain weights?
The 60 concepts are distributed as 33 advanced hepatology/pretransplant, 8 peritransplant, 12 post-transplant, 4 immunology and 3 ethics/regulation concepts. The 20 questions and 20 flashcards each use an 11/3/4/1/1 distribution. These approximate the official domain targets. The expanded outline remains the complete scope, including important conditions not individually developed in this selective guide.
Transplant Hepatology Certification Examination — Expanded Blueprint
Which jurisdiction applies to the allocation and donor-policy material?
The OPTN allocation, living-donor selection and information-sharing material is specific to the United States. Policy examples use the OPTN policies effective October 1, 2026. Clinical guidance also includes international society recommendations, but those recommendations do not establish US allocation eligibility or replace current OPTN requirements.
OPTN Policies — Effective October 1, 2026 · HRSA/OPTN Guidance for Donor and Recipient Information Sharing
This guide addresses the ABIM-administered Transplant Hepatology Certification Examination, a subspecialty certification within the jointly developed ABIM/ABP program. The guide, questions and flashcards are independently authored educational materials without ABIM endorsement.
Outline used: January 2026 initial certification blueprint, implemented beginning Fall 2026. The current expanded CERT outline was opened and cross-checked on 2026-10-09. The workbook label maps to ABIM's Transplant Hepatology Certification Examination; the assigned slug is retained.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Advanced Hepatology and Pretransplant55%
1.Which findings make Wilson disease an urgent acute liver failure diagnosis?
Wilson disease can cause rapidly progressive liver failure accompanied by Coombs-negative intravascular hemolysis as copper released from injured hepatocytes damages erythrocytes. Severe jaundice with unexpectedly low alkaline phosphatase, hemolysis and renal dysfunction is an important diagnostic pattern. Ceruloplasmin alone cannot confirm or exclude the diagnosis in this setting. Suspected Wilson-associated acute liver failure requires urgent transplant evaluation because medical copper removal cannot be relied upon to reverse fulminant deterioration.
Apply it
A young adult develops encephalopathy, worsening INR, marked jaundice and anemia with a negative direct antiglobulin test. Recognize the combined hepatic and hemolytic pattern, arrange copper-focused testing, and contact a transplant center immediately.
Common pitfall: Waiting for a low ceruloplasmin result before referral can lose critical time. A normal result does not safely exclude Wilson-associated acute liver failure.
2.Which renal findings support simultaneous liver-kidney allocation rather than assuming recovery after liver transplantation?
US OPTN medical eligibility distinguishes chronic kidney disease from sustained acute kidney injury. The CKD pathway requires GFR at most 60 mL/min for more than 90 consecutive days plus regular ESRD dialysis or qualifying GFR/creatinine clearance at most 30 mL/min at or after kidney-list registration. Sustained AKI requires dialysis at least weekly, GFR/creatinine clearance at most 25 mL/min at least weekly, or a combination, throughout the preceding six weeks. Transplant-nephrologist confirmation and documentation are required. Eligibility informs allocation; renal trajectory and recovery potential still guide clinical selection.
Apply it
A candidate has GFR 42 mL/min for five months and 27 mL/min at kidney-list registration. This supports the CKD medical-eligibility pathway; a single creatinine rise during a short infection would not establish the same chronicity.
Common pitfall: One low GFR does not demonstrate sustained AKI or CKD. Meeting medical eligibility also does not bypass the other liver-kidney allocation requirements.
3.How do tumor burden and biologic response change HCC transplant decisions?
An imaging diagnosis must be followed by staging and assessment of tumor biology. Milan criteria describe one tumor at most 5 cm or up to three tumors each at most 3 cm, without macrovascular invasion or extrahepatic spread. Selected patients beyond these limits may undergo liver-directed downstaging. High or rising AFP and progression despite treatment suggest greater recurrence risk. Under US standardized-exception policy, a prior AFP above 1,000 ng/mL requires reduction below 500 ng/mL after treatment and maintenance below that level; size response alone is insufficient.
Apply it
A patient has a solitary 3-cm HCC but AFP remains 1,200 ng/mL after treatment. Favorable size does not neutralize the adverse biologic signal or satisfy the standardized AFP requirement.
Common pitfall: LR-5 establishes an imaging diagnosis, not favorable tumor biology, complete staging or automatic transplant priority.
EASL Clinical Practice Guidelines on Liver Transplantation — 2024 · OPTN Policies — Effective October 1, 2026
4.Why is budesonide unsuitable for autoimmune hepatitis with cirrhosis?
Budesonide depends on extensive hepatic first-pass metabolism to limit systemic glucocorticoid exposure. Cirrhosis and portosystemic shunting disrupt that advantage, producing less predictable exposure and greater safety concerns. It should not be used for autoimmune hepatitis in patients with cirrhosis. Induction requires a suitable systemic corticosteroid-based strategy, with additional immunosuppression selected according to disease severity and patient factors. Reducing steroid adverse effects must not override a contraindication created by altered hepatic physiology.
Apply it
A patient with biopsy-supported autoimmune hepatitis has varices and nodular liver morphology. Although diabetes makes steroid toxicity concerning, choose an appropriate systemic induction strategy rather than substituting budesonide to reduce anticipated metabolic adverse effects.
Common pitfall: Describing budesonide as universally safer overlooks its dependence on preserved first-pass metabolism. Cirrhosis changes drug handling and removes the rationale for this substitution.
EASL Clinical Practice Guidelines on Autoimmune Hepatitis — 2025
5.When does autoimmune hepatitis response justify considering treatment withdrawal?
Complete biochemical response requires normal aminotransferases and IgG. The 2025 EASL recommendation restricts a withdrawal trial to carefully selected patients whose low-dose monotherapy has maintained stable complete biochemical response for at least two years. Reduce immunosuppression stepwise and assess residual activity using aminotransferases, IgG and, when appropriate, biopsy, because residual inflammation predicts relapse. Most patients need long-term treatment. After cessation, monitor for relapse at least every three months during the first year and continue individualized surveillance indefinitely.
Apply it
A patient feels well after several months, but IgG remains elevated despite nearly normal ALT. Complete biochemical response has not been achieved, and the duration and treatment conditions for a withdrawal trial are unmet.
Common pitfall: Two years since diagnosis is not two years of stable complete biochemical response on low-dose monotherapy. Relapse can occur many years after withdrawal.
EASL Clinical Practice Guidelines on Autoimmune Hepatitis — 2025
6.How should autoimmune hepatitis treatment be approached during pregnancy planning?
Aim for stable disease control with pregnancy-compatible treatment. Corticosteroids and azathioprine can continue when appropriate; abrupt withdrawal risks a flare, including postpartum. For AIH, EASL recommends withdrawing mycophenolate at least three months before conception while establishing an effective alternative. This society recommendation differs from the US CELLCEPT label's requirement for acceptable contraception throughout treatment and for six weeks after stopping. Following the shorter contraception interval alone does not fulfill the AIH guideline's preconception recommendation.
Apply it
A patient taking mycophenolate hopes to conceive in four weeks. Establish an alternative regimen and postpone conception to meet the recommended interval while confirming continued disease control.
Common pitfall: An immediate medication substitution does not complete pregnancy preparation. Mycophenolate's fetal risk should not be generalized to all maintenance therapies.
EASL Clinical Practice Guidelines on Autoimmune Hepatitis — 2025 · CELLCEPT Prescribing Information
7.What supports primary biliary cholangitis diagnosis and initial treatment?
Primary biliary cholangitis is supported by a cholestatic biochemical pattern together with antimitochondrial antibodies or other disease-specific evidence, after extrahepatic obstruction is excluded. Biopsy is particularly useful when the presentation is atypical or overlap disease is suspected. Ursodeoxycholic acid is foundational initial therapy for patients with abnormal liver biochemistry. Assess biochemical response after approximately 12 months: persistent alkaline phosphatase elevation and increased bilirubin identify greater progression risk, even when itching improves.
Apply it
A patient has persistent alkaline phosphatase elevation, positive antimitochondrial antibodies and imaging without obstruction. Initiate appropriate ursodeoxycholic acid treatment and plan biochemical risk reassessment rather than requiring a biopsy solely to repeat an otherwise coherent diagnostic pattern.
Common pitfall: Pruritus severity does not reliably measure progression or treatment response. Symptom relief cannot substitute for assessment of alkaline phosphatase, bilirubin and disease stage.
AASLD Primary Biliary Cholangitis Practice Guidance — 2018 · AASLD Primary Biliary Cholangitis Guidance Index
8.How is cholestatic pruritus treated without compromising other oral therapy?
Assess for obstruction and treat the underlying cholestatic disease. Cholestyramine is a usual initial pharmacologic option for pruritus, but intestinal binding can reduce absorption of other medicines. Administer ursodeoxycholic acid at least one hour before or four hours after the bile acid sequestrant. Other oral drugs require their own interaction review. Persistent itching warrants a staged alternative strategy with attention to hepatic safety rather than simply escalating sedating medications.
Apply it
A usable schedule is ursodeoxycholic acid at 08:00 and cholestyramine at 09:00. If cholestyramine is taken first at 08:00, defer ursodeoxycholic acid until at least 12:00.
Common pitfall: Taking both medicines together can reduce ursodeoxycholic acid absorption. Sedation from an antihistamine should not be mistaken for effective treatment of cholestatic itch.
9.When does primary sclerosing cholangitis require therapeutic ERCP?
MR cholangiography generally evaluates suspected primary sclerosing cholangitis without the procedural risks of diagnostic ERCP. ERCP becomes appropriate when an actionable ductal problem is suspected, including a relevant stricture associated with obstruction, concerning clinical deterioration or bacterial cholangitis responding inadequately to antibiotics. It can provide drainage and appropriate sampling. The distinction is between defining biliary anatomy noninvasively and treating or investigating a clinically significant obstruction that imaging alone cannot resolve.
Apply it
A patient with established primary sclerosing cholangitis remains febrile and jaundiced despite antibiotics, with imaging showing a high-grade ductal narrowing. Arrange therapeutic ERCP for drainage and assessment instead of repeating noninvasive imaging without addressing obstruction.
Common pitfall: ERCP is not a routine substitute for MR cholangiography in stable diagnostic evaluation. Conversely, antibiotics alone may fail when an obstructed infected system needs drainage.
AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma
10.Why does PSC-associated inflammatory bowel disease require intensified colorectal surveillance?
Primary sclerosing cholangitis associated with inflammatory bowel disease carries increased colorectal neoplasia risk, even when intestinal symptoms are mild. Adults with PSC and IBD generally undergo surveillance colonoscopy at one- to two-year intervals, using appropriate high-quality examination and dysplasia assessment. Symptom control does not eliminate cancer risk, and liver transplantation does not remove the need for surveillance. The key cue is the combined PSC-IBD phenotype rather than the apparent intensity of colitis symptoms.
Apply it
A patient with PSC and clinically quiet ulcerative colitis asks to return to average-risk screening after transplantation. Explain that the combined disease phenotype continues to require frequent surveillance despite a successful graft and minimal bowel symptoms.
Common pitfall: Using average-risk screening intervals because colitis is asymptomatic overlooks persistent neoplasia risk. Transplantation treats liver failure but does not abolish PSC-associated colorectal risk.
AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma
11.Why must hepatitis B suppression continue across liver transplantation?
Liver transplantation does not guarantee eradication of hepatitis B reservoirs, and subsequent immunosuppression favors viral replication. Potent nucleos(t)ide analogue therapy with a high barrier to resistance is central to preventing graft reinfection. Hepatitis B immunoglobulin use is individualized according to recurrence risk and the transplant strategy rather than assumed to be identical for every recipient. Viral suppression before transplantation and a defined post-transplant prevention plan are complementary parts of care.
Apply it
A candidate with hepatitis B cirrhosis has undetectable HBV DNA on antiviral treatment and asks whether medication can stop when the native liver is removed. Explain the persistence of infection risk and establish ongoing prevention before transplantation.
Common pitfall: An undetectable pretransplant viral load reflects suppression rather than assured eradication. Removing the native liver does not justify abandoning hepatitis B prevention.
EASL Clinical Practice Guidelines on Liver Transplantation — 2024
12.How do hepatitis C antibody and RNA results answer different questions?
Hepatitis C antibody indicates exposure and can remain positive after spontaneous clearance or successful treatment. Detectable HCV RNA establishes current viremia and is the decisive test when determining active infection. Recent exposure and immunosuppression complicate interpretation because antibody responses may be absent or delayed. In transplant evaluation, separating prior exposure from current replication prevents unnecessary labeling while ensuring that active infection and potential donor-derived transmission receive appropriate planning and follow-up.
Apply it
A transplant candidate previously cured of hepatitis C has a positive antibody result during reassessment. Check HCV RNA before diagnosing recurrent infection; the antibody result alone cannot distinguish previous cure from current viral replication in this patient.
Common pitfall: A positive antibody is not proof of current infection. A negative antibody also cannot reliably exclude very recent infection in a high-risk exposure setting.
13.How does Budd-Chiari syndrome differ from portal vein thrombosis?
Budd-Chiari syndrome obstructs hepatic venous outflow; portal vein thrombosis obstructs portal inflow. Diagnose Budd-Chiari by demonstrating outflow obstruction or characteristic hepatic venous collaterals with absent patent hepatic veins. Primary Budd-Chiari generally requires long-term anticoagulation and assessment for an underlying prothrombotic disorder. Look for short stenoses amenable to angioplasty or stenting. Persistent disease despite medical therapy, when focal intervention is unsuitable, supports TIPS; uncontrolled failure can require transplantation. Biopsy is unnecessary when vascular imaging establishes the obstruction.
Apply it
Painful hepatomegaly and new ascites persist despite a patent portal vein. Examine the hepatic veins and inferior vena cava; portal patency does not evaluate the suspected outflow problem.
Common pitfall: A patent portal vein does not exclude Budd-Chiari syndrome. Nodules in this vascular setting also require separate assessment because benign hyperplastic nodules can mimic HCC.
14.Why does portal vein thrombosis matter during transplant evaluation?
Portal vein thrombosis can complicate restoration of portal inflow during transplantation, particularly when extensive or involving mesenteric veins. Characterize its extent, chronicity and progression, and distinguish bland thrombosis from tumor invasion. EASL recommends anticoagulation for transplant candidates with cirrhosis and newly diagnosed bland portal vein thrombosis, with individualized assessment of contraindications and bleeding risk. Preserving or restoring portal patency helps maintain transplant options. Selected patients may require portal vein recanalization with TIPS, particularly when anticoagulation does not restore adequate patency or thrombosis would prevent a suitable portal anastomosis.
Apply it
A listed patient with cirrhosis develops new partial bland portal vein thrombosis. Define the vascular anatomy and assess contraindications, then initiate anticoagulation if no contraindication is identified. Follow portal patency with imaging. Consider recanalization/TIPS in selected cases if adequate portal inflow cannot otherwise be preserved.
Common pitfall: Neither partial occlusion nor an absence of symptoms justifies ignoring newly diagnosed bland thrombosis in a transplant candidate. Conversely, anticoagulation is not a treatment for tumor invasion. Extensive thrombosis increases surgical complexity but does not automatically exclude transplantation.
EASL Clinical Practice Guidelines on Liver Transplantation — 2024
15.What does the serum-ascites albumin gradient establish?
The serum-ascites albumin gradient is calculated by subtracting ascitic albumin from serum albumin measured in the same clinical period. A gradient of at least 1.1 g/dL supports portal hypertension as the mechanism of ascites. It does not identify cirrhosis as the only possible cause: cardiac congestion and other vascular disorders can also produce a high gradient. Ascitic total protein and the broader clinical picture help distinguish causes after the portal-hypertensive mechanism is recognized.
Apply it
Serum albumin is 3.4 g/dL and ascitic albumin is 1.8 g/dL, giving a gradient of 1.6 g/dL. Identify portal-hypertensive physiology, then use cardiac findings, imaging and ascitic protein to refine its cause.
Common pitfall: A high gradient does not prove cirrhosis. Using the gradient as an etiologic diagnosis can obscure cardiac congestion or another vascular cause.
AASLD Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome Practice Guidance — 2021
16.When should ascitic neutrophils trigger treatment for spontaneous bacterial peritonitis?
An ascitic polymorphonuclear leukocyte count of at least 250 cells/µL supports treatment for spontaneous bacterial peritonitis in the appropriate clinical setting. Calculate the absolute neutrophil count from the total cell count and neutrophil fraction when necessary. A negative culture does not negate neutrocytic ascites, and treatment should not wait for culture growth. Marked abdominal findings, unusual organisms or an inadequate response should also prompt consideration of a surgically treatable secondary source.
Apply it
Ascitic fluid contains 900 leukocytes/µL with 35% neutrophils, producing 315 neutrophils/µL. Begin appropriate empirical treatment while cultures are pending, even if the patient has no fever and the initial Gram stain is negative.
Common pitfall: Using the total leukocyte count instead of the absolute neutrophil count misclassifies fluid. Waiting for a positive culture delays treatment of culture-negative neutrocytic ascites.
AASLD Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome Practice Guidance — 2021
17.What establishes HRS-AKI, and when should syndrome-directed treatment begin?
The 2024 ICA-ADQI criteria require cirrhosis with ascites; creatinine increase of at least 0.3 mg/dL within 48 hours or at least 50% within seven days, and/or urine output at most 0.5 mL/kg/hour for at least six hours; no improvement within 24 hours after adequate resuscitation when indicated; and no strong alternative primary explanation. Mandatory 48-hour albumin administration is no longer required. HRS can coexist with tubular injury, proteinuria or CKD. Once established, initiate a vasoconstrictor, preferably terlipressin when suitable, with albumin adjusted to volume status. Norepinephrine is an alternative requiring an appropriate monitored setting.
Apply it
Ascitic cirrhosis is accompanied by creatinine rising from 1.0 to 1.6 mg/dL over three days. Correct indicated volume depletion and assess infection, sediment, obstruction and nephrotoxins. Persistent dysfunction after 24 hours without a stronger primary cause supports HRS-AKI treatment. Assess oxygenation and overload before therapy and repeatedly thereafter.
Common pitfall: Automatic albumin loading in a euvolemic or overloaded patient can worsen pulmonary edema. Hypoxemia, respiratory deterioration and ischemic risk materially affect vasoconstrictor safety and albumin administration.
18.Which acute variceal bleeding patients benefit from preemptive TIPS?
Preemptive TIPS targets patients at high risk of failing standard acute variceal bleeding treatment, before uncontrolled rebleeding occurs. Baveno VII identifies Child-Pugh C patients with fewer than 14 points and Child-Pugh B patients above 7 points with active bleeding at initial endoscopy among the principal eligible groups. Placement should occur within 72 hours, ideally within 24 hours, when appropriate. Initial bleeding control does not remove the indication in an otherwise suitable high-risk patient.
Apply it
A patient with Child-Pugh C cirrhosis scored at 11 points undergoes successful banding for acute esophageal variceal bleeding. Assess suitability for preemptive TIPS promptly rather than waiting to see whether another major hemorrhage develops.
Common pitfall: Preemptive TIPS is not reserved for failed endoscopic hemostasis. Waiting for rebleeding misses the intended prevention window in a selected high-risk patient.
19.Why is albumin used after large-volume paracentesis, and how is replacement calculated?
Large-volume paracentesis can worsen effective arterial underfilling through postparacentesis circulatory dysfunction. When more than 5 L is removed, AASLD recommends 6–8 g albumin per liter of total ascites removed, not only the volume above 5 L. The indication concerns hemodynamic consequences rather than simply low serum albumin. Concentrated 20–25% preparations can limit infused volume; calculate grams first, then convert to the available formulation and monitor circulatory and respiratory status.
Apply it
Removal of 7 L requires 7 × 6–8 g, or 42–56 g albumin. With a 25% formulation containing 25 g per 100 mL, this corresponds to 168–224 mL before practical preparation and dosing decisions.
Common pitfall: Replacing only the final 2 L underestimates the recommendation. Relief of abdominal pressure does not establish stable circulation or kidney function.
AASLD Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome Practice Guidance — 2021
20.Why should protein restriction be avoided in hepatic encephalopathy?
Skeletal muscle contributes to ammonia handling, and muscle loss worsens vulnerability to hepatic encephalopathy. Restricting dietary protein can aggravate malnutrition and sarcopenia without providing a durable solution to encephalopathy. Management should identify precipitants, use appropriate encephalopathy therapy and maintain adequate nutrition, including avoidance of prolonged fasting. Protein intake and meal planning should support muscle preservation; the choice of tolerated protein sources can be adjusted without adopting chronic global protein restriction.
Apply it
A patient with recurrent encephalopathy has lost substantial muscle after following a low-protein diet. Restore an appropriate nutritional plan while treating constipation and reviewing medications, rather than further restricting protein because the ammonia concentration remains elevated.
Common pitfall: An elevated ammonia value does not justify progressive protein deprivation. Nutritional harm can worsen the muscle deficit that contributes to impaired ammonia handling.
AASLD Malnutrition, Frailty and Sarcopenia Practice Guidance — 2021
21.Why does INR poorly represent bleeding risk during variceal hemorrhage?
Cirrhosis reduces both procoagulant and anticoagulant factors, creating a rebalanced but fragile hemostatic state that INR does not fully describe. Variceal bleeding is primarily driven by portal pressure and vascular rupture rather than an isolated deficiency reflected by INR. Routine fresh frozen plasma administration to normalize INR is not recommended during acute variceal bleeding and can worsen volume overload. Effective management prioritizes resuscitation, vasoactive therapy, antibiotics, endoscopic control and appropriate portal-pressure intervention.
Apply it
A patient with variceal hemorrhage has an INR of 2.1 but no separate indication for plasma. Focus on evidence-based bleeding control instead of delaying endoscopy while attempting to normalize the INR with large-volume plasma transfusion.
Common pitfall: Treating the INR as a direct bleeding-risk meter overlooks reduced anticoagulant factors. Plasma volume can worsen the hemodynamic conditions driving portal-hypertensive bleeding.
22.Who is eligible for CT/MRI LI-RADS, and when can an observation be LR-5?
Diagnostic CT/MRI LI-RADS applies to adults at high HCC risk because of cirrhosis, chronic hepatitis B, or current or prior HCC. Exclusions include congenital hepatic fibrosis and cirrhosis from vascular disorders such as Budd-Chiari syndrome, chronic portal vein occlusion, cardiac congestion, hereditary hemorrhagic telangiectasia and diffuse nodular regenerative hyperplasia. Benign hyperplastic nodules in these conditions can mimic HCC. In an eligible patient, an observation at least 20 mm with nonrim arterial enhancement and nonperipheral washout can meet LR-5 criteria.
Apply it
An adult with hepatitis C-related cirrhosis has a 24-mm observation with nonrim arterial hyperenhancement and nonperipheral washout on adequate MRI. This supports LR-5. The same appearance in Budd-Chiari syndrome cannot be assigned equivalent diagnostic certainty through this algorithm.
Common pitfall: Cirrhosis alone does not establish eligibility when its cause is excluded. LR-5 also does not independently establish allocation-exception eligibility.
23.How does LR-M change the interpretation of a malignant liver observation?
LR-M means probably or definitely malignant but not specific for hepatocellular carcinoma. Targetoid features, such as rim arterial phase enhancement, can suggest cholangiocarcinoma or another non-HCC malignancy, although some HCCs also receive this category. The category therefore signals the need for further diagnostic characterization rather than permission to assume conventional HCC. Histologic clarification can be important because tumor identity changes treatment, transplant consideration and the interpretation of allocation criteria.
Apply it
A patient with cirrhosis has a liver mass with rim enhancement and targetoid diffusion features. Discuss tissue diagnosis and multidisciplinary evaluation instead of assigning an HCC-specific treatment pathway solely because the background liver is cirrhotic.
Common pitfall: LR-M is not synonymous with cholangiocarcinoma, and malignancy is not synonymous with HCC. The imaging category preserves uncertainty about the tumor's specific identity.
24.How should frailty influence transplant evaluation?
Frailty captures impaired physiologic reserve and predicts adverse outcomes beyond conventional liver severity measures. It should be measured consistently and followed over time alongside nutrition, functional status and potentially reversible contributors. Frailty identifies a need for rehabilitation and nutritional intervention, not an automatic exclusion based on one measurement. Decisions integrate the trajectory, comorbidities and feasibility of improvement, recognizing that ascites and obesity can conceal substantial muscle depletion despite an apparently adequate body weight.
Apply it
A candidate with obesity has weak grip strength, slow chair stands and declining activity. Assess sarcopenia and nutrition, initiate individualized rehabilitation, and follow functional change rather than interpreting body mass index as evidence of adequate physiologic reserve.
Common pitfall: A high body mass index does not exclude sarcopenia. Using one frailty score as an absolute listing rule discards context and potentially reversible deficits.
AASLD Malnutrition, Frailty and Sarcopenia Practice Guidance — 2021
25.What establishes acute liver failure and signals worsening prognosis?
Acute liver failure requires acute hepatic injury with illness lasting less than 26 weeks, INR at least 1.5 and hepatic encephalopathy, ordinarily without preexisting cirrhosis. Recognized exceptions include Wilson disease, in which underlying chronic pathology does not exclude an acute liver failure presentation. Arrange immediate transplant-center referral and etiologic investigation without waiting for prognostic thresholds. Begin N-acetylcysteine promptly when acetaminophen injury is suspected, even if a late drug concentration is undetectable. Follow encephalopathy, INR, lactate, glucose, kidney function and hemodynamic support requirements. Falling aminotransferases alongside worsening synthetic function can reflect loss of viable hepatocytes rather than recovery.
Apply it
A previously healthy patient develops confusion and INR 2.3 during a one-week illness after repeated excess acetaminophen use. This meets the conventional acute liver failure definition. Start N-acetylcysteine and arrange immediate transplant-center care. Increasing encephalopathy and lactate despite falling ALT indicate deterioration.
Common pitfall: Coagulopathy without encephalopathy does not establish acute liver failure. Neither disappearance of acetaminophen from blood nor falling ALT establishes recovery. Prognostic criteria help assess transplantation needs; they are not prerequisites for referral.
AASLD: Defining and Managing Acute Liver Failure · Acute%20Liver%20Failure%20Update2011.pdf
26.How do hepatopulmonary syndrome and portopulmonary hypertension change transplant assessment?
Hepatopulmonary syndrome combines liver disease or portal hypertension, impaired oxygenation and intrapulmonary vascular dilatation or shunting. Portopulmonary hypertension instead involves increased pulmonary vascular resistance; echocardiography screens, and right-heart catheterization establishes the hemodynamic pattern. An elevated pulmonary pressure alone may reflect high flow or volume overload. EASL identifies mean pulmonary arterial pressure above 45 mmHg despite vasomodulator treatment as a transplant contraindication because of perioperative risk. HPS clinical diagnosis and US standardized-exception qualification are separate determinations.
Apply it
A candidate has mean pulmonary arterial pressure 48 mmHg, PVR 6 Wood units and wedge pressure 10 mmHg despite treatment. This resistance-associated pattern requires pulmonary vascular management and reassessment, rather than treating hypoxemia as sufficient evidence of HPS.
Common pitfall: Contrast-echo shunting and high pulmonary vascular resistance indicate different mechanisms. A low laboratory MELD does not eliminate pulmonary risk or automatically confer exception priority.
EASL Clinical Practice Guidelines on Liver Transplantation — 2024 · OPTN Policies — Effective October 1, 2026
27.Which vaccination and bone-health decisions should be anticipated before transplantation?
Review vaccination needs before immunosuppression limits options. During CELLCEPT treatment, avoid live attenuated vaccines, including intranasal influenza, and recognize that vaccine responses may be reduced; injectable nonlive influenza vaccination avoids that live-vaccine problem. In PBC, assess bone mineral density approximately every two years, individualized to baseline density and cholestasis. Osteoporosis warrants treatment consideration, but AASLD advises avoiding oral bisphosphonates in patients with known varices or acid reflux; choose an appropriate alternative route after assessing renal function and mineral status.
Apply it
A PBC candidate with osteoporosis and esophageal varices needs a bone-treatment plan that avoids oral esophageal injury. Document vaccination needs now and anticipate selecting nonlive formulations during subsequent mycophenolate therapy.
Common pitfall: Stable liver tests do not establish adequate bone health. A live intranasal vaccine and a nonlive injectable vaccine are not interchangeable during immunosuppression.
AASLD Primary Biliary Cholangitis Practice Guidance — 2018 · CELLCEPT Prescribing Information
28.How does the Lille score change corticosteroid treatment in alcohol-associated hepatitis?
The Lille score evaluates early response after corticosteroid treatment for severe alcohol-associated hepatitis, incorporating the bilirubin trajectory and other clinical variables. A score above 0.45 identifies poor response and supports stopping corticosteroids because continued exposure is unlikely to provide benefit while infection and other risks persist. It is a response tool, not the initial diagnostic test or a standalone transplant eligibility rule. Clinical complications and contraindications still require reassessment throughout treatment.
Apply it
A patient receiving corticosteroids for severe alcohol-associated hepatitis has a day-7 Lille score of 0.71. Reconsider and discontinue ineffective corticosteroid treatment while addressing complications, nutrition, alcohol-use treatment and potential transplant evaluation when appropriate.
Common pitfall: Continuing corticosteroids solely because the initial disease was severe ignores response information. The Lille score measures treatment response rather than certifying candidacy for transplantation.
AASLD Alcohol-Associated Liver Disease Practice Guidance — 2019
29.Why should alcohol-related transplant selection extend beyond a fixed abstinence interval?
A fixed abstinence interval is an incomplete predictor of sustained recovery from alcohol use disorder and can delay assessment in patients unlikely to survive that interval. Selection should examine relapse risk, treatment engagement, psychiatric illness, prior recovery attempts, adherence and available support. Carefully selected patients with severe alcohol-associated disease may be considered without a universal six-month requirement. Individualized evaluation does not remove the need for addiction treatment, transparent selection and longitudinal monitoring before and after transplantation.
Apply it
A patient with severe alcohol-associated hepatitis has little chance of surviving six months but demonstrates treatment engagement and a favorable multidisciplinary psychosocial assessment. Consider individualized transplant evaluation rather than rejecting referral solely because a calendar threshold is unmet.
Common pitfall: Abandoning a fixed interval does not mean ignoring relapse risk. Conversely, completing six months of abstinence does not independently establish psychosocial suitability.
AASLD Alcohol-Associated Liver Disease Practice Guidance — 2019 · AASLD: Evolution of the Six-Month Sobriety Rule
30.How should fibrosis risk be assessed sequentially in MASLD?
Use FIB-4 to triage advanced-fibrosis risk rather than relying on ALT or steatosis alone. Through age 65, FIB-4 below 1.3 generally indicates low risk; above age 65, the lower decision threshold becomes 2.0 because age increases the score and false-positive results. Intermediate results, from the age-adjusted lower threshold through 2.67, generally warrant second-stage assessment with elastography or another validated fibrosis test. Results above 2.67 warrant specialist assessment. For selected intermediate-risk patients, EASL also permits intensified cardiometabolic management followed by reassessment within one year; persistent FIB-4 elevation should then prompt elastography.
Apply it
A 58-year-old with type 2 diabetes, steatosis and normal ALT has FIB-4 of 1.8. This is intermediate risk and supports second-stage fibrosis assessment. Selected patients may instead undergo intensified cardiometabolic management and reassessment within one year, followed by elastography if elevation persists. At age 72, the same score falls below the age-adjusted lower threshold of 2.0.
Common pitfall: Low-risk FIB-4 does not guarantee absence of advanced fibrosis, and normal ALT does not exclude it. FIB-4 is a triage score, not a histologic diagnosis. Do not apply the 1.3 threshold indiscriminately above age 65 or postpone specialist assessment when FIB-4 exceeds 2.67.
31.Which weight-loss goals correspond to different MASLD outcomes?
Sustained weight loss has graded effects in adults with MASLD and overweight or obesity. The 2024 EASL-EASD-EASO guideline associates at least 5% loss with reduced liver fat, 7–10% with improved inflammation and at least 10% with improved fibrosis. These are treatment goals rather than guarantees for an individual. Nutrition, physical activity and management of diabetes and cardiovascular risk remain essential, with muscle preservation particularly important when advanced liver disease or frailty is present.
Apply it
A patient weighing 100 kg asks whether losing 5 kg is sufficient to target fibrosis improvement. Explain that this may reduce steatosis, while a sustained loss of approximately 10 kg is the guideline goal associated with fibrosis improvement.
Common pitfall: A weight-loss threshold is not a promise of histologic reversal. Pursuing rapid weight loss without preserving nutrition and muscle can harm a frail patient.
32.How does acute-on-chronic liver failure change transplant urgency?
Acute-on-chronic liver failure involves acute deterioration of chronic liver disease with organ failure and high short-term mortality. Definitions differ between major frameworks, so the framework should be identified when interpreting severity scores or studies. Management searches rapidly for reversible precipitants, such as infection or bleeding, while supporting failing organs and assessing transplant suitability. Dynamic organ-failure progression matters more than treating the episode as an uncomplicated increase in ascites or bilirubin within otherwise stable cirrhosis.
Apply it
A patient with cirrhosis develops infection, encephalopathy, acute kidney injury and vasopressor-dependent shock. Treat the precipitant and organ failures while urgently assessing transplant options rather than waiting for outpatient severity scoring after the infection has resolved.
Common pitfall: Acute decompensation and acute-on-chronic liver failure are not interchangeable labels. Organ failure and the chosen diagnostic framework determine the severity interpretation and urgency.
EASL Clinical Practice Guidelines on Liver Transplantation — 2024
33.When should palliative care accompany transplant-focused treatment?
Palliative care addresses symptoms, communication, decision-making and family support in serious liver disease and can accompany active transplant evaluation. Referral does not require abandoning disease-directed treatment or proving that transplantation is impossible. Recurrent hospitalization, substantial symptom burden and uncertain outcomes justify discussing patient priorities and contingency plans. Connect the likely benefits and burdens of interventions with those goals, including what should happen if transplantation becomes unavailable. These principles are developed in the [AASLD palliative-care guidance](https://onlinelibrary.wiley.com/doi/full/10.1002/hep.32378).
Apply it
A listed patient has repeated admissions for painful ascites and asks what care would look like if transplantation never occurs. Arrange concurrent symptom and goals-of-care support while continuing appropriate transplant treatment and evaluation.
Common pitfall: Equating palliative care with immediate withdrawal of treatment delays useful support. A transplant listing does not eliminate symptom burden or the need for contingency planning.
Transplant Hepatology Certification Examination — Expanded Blueprint
Peritransplant14%
34.Why are DCD grafts vulnerable to ischemic cholangiopathy?
Donation after circulatory death exposes the graft to a period of warm ischemia before preservation, with particular concern for injury to the biliary microcirculation. Subsequent nonanastomotic biliary strictures can occur despite a patent main hepatic artery. A randomized trial of oxygenated hypothermic machine perfusion in DCD liver transplantation demonstrated fewer nonanastomotic biliary strictures than conventional static cold storage. The finding supports a preservation strategy for a defined risk, rather than implying that perfusion eliminates all donor-related complications.
Apply it
A DCD graft offer raises concern about later nonanastomotic strictures. Discuss ischemic exposure and the center's preservation approach, including oxygenated hypothermic perfusion where available, rather than judging biliary risk solely from a patent donor hepatic artery.
Common pitfall: A patent large hepatic artery does not exclude ischemic injury to the biliary microcirculation. Trial results should not be generalized to every perfusion technology.
Hypothermic Machine Perfusion in Liver Transplantation — A Randomized Trial
35.How should deceased-donor graft risks be combined?
Deceased-donor assessment combines donor characteristics, steatosis, ischemic exposure, infection findings and recipient condition. Macrovesicular steatosis can increase vulnerability to ischemia-reperfusion injury, so its significance changes when prolonged preservation or other donor risks are also present. Acceptance is a donor-recipient matching decision that compares expected graft outcomes with the candidate's risk of waiting. No single favorable feature neutralizes every other risk, and no isolated risk characteristic automatically describes the net benefit for every recipient.
Apply it
A candidate with rapidly worsening disease receives an offer involving steatosis and anticipated prolonged cold storage. Evaluate the combined graft risks against waiting-list risk and available alternatives rather than applying an isolated donor characteristic as a universal acceptance rule.
Common pitfall: Counting risk factors without considering their interaction and the recipient's urgency can mislead. A graft's suitability is not identical for every candidate.
EASL Clinical Practice Guidelines on Liver Transplantation — 2024
36.How is living-donor remnant volume used in US donor selection?
Living liver donation must leave adequate functional liver for the donor while providing an appropriate graft for the recipient. Under the cited US OPTN policy, an expected donor remnant below 30% of native liver volume is an exclusion criterion. Remnant percentage is calculated as planned remaining volume divided by total native volume. Volume assessment must also consider anatomy and liver quality; meeting a numerical minimum does not independently establish acceptable operative risk or donor suitability.
Apply it
A donor has a native liver volume of 1,500 mL and a proposed remnant of 390 mL. The remnant is 26%, below the cited US policy threshold, so the proposed donation cannot proceed on that plan.
Common pitfall: A graft large enough for the recipient can still leave an unsafe donor remnant. Passing volumetric criteria also does not replace a complete donor evaluation.
37.Why must ABO compatibility and identity be verified independently?
ABO compatibility concerns recipient antibodies against donor blood-group antigens and is distinct from HLA matching or donor-specific HLA antibodies. US transplant safeguards require controlled blood-type determination, documentation and verification procedures to prevent incompatible or incorrectly identified transplantation. A conversational report of blood type cannot substitute for these processes. When ABO-incompatible transplantation is considered, it requires an intentional specialized strategy; it must never result from assuming that another form of compatibility testing establishes ABO safety.
Apply it
A living donor reports the same blood group as the intended recipient, and HLA testing appears favorable. Complete the required independent blood-type and identity verification procedures rather than treating verbal history or HLA findings as sufficient compatibility evidence.
Common pitfall: HLA compatibility does not establish ABO compatibility. Administrative verification is a clinical safety barrier, even when the donor and recipient know each other well.
38.How does small-for-size syndrome differ from simple graft size measurement?
Small-for-size syndrome reflects inadequate functional graft capacity relative to recipient demands and portal inflow, rather than a volume number alone. A partial graft may develop persistent cholestasis, coagulopathy and ascites when excessive portal flow injures a limited vascular bed. Assessment must exclude outflow obstruction, arterial or portal compromise, rejection and infection. Graft quality, recipient condition and portal hemodynamics affect risk. The [ILTS-iLDLT-LTSI consensus](https://hub.hku.hk/handle/10722/342684) addresses the diagnostic timing and clinical features.
Apply it
A recipient of a partial living-donor graft develops persistent ascites, rising bilirubin and poor synthetic recovery. Assess portal inflow and venous outflow alongside graft size and quality rather than assuming that successful implantation excludes a size-related functional problem.
Common pitfall: A measured graft volume does not capture all functional risk. Similar postoperative findings can arise from vascular obstruction and must not be labeled prematurely.
EASL Clinical Practice Guidelines on Liver Transplantation — 2024
39.When should early graft dysfunction raise concern for primary nonfunction?
Early allograft dysfunction spans a range of postoperative injury, whereas primary nonfunction describes catastrophic failure of the graft to sustain the recipient. Persistent severe coagulopathy, metabolic acidosis, poor lactate clearance and hemodynamic instability are concerning when they do not improve. Urgent evaluation must exclude treatable technical problems, especially vascular compromise. A deteriorating trajectory requires immediate transplant-team assessment and possible retransplant planning rather than waiting for routine postoperative biochemical abnormalities to resolve spontaneously.
Apply it
After transplantation, a patient has worsening acidosis, rising lactate and escalating vasopressor needs despite resuscitation. Obtain urgent vascular and graft assessment while discussing possible retransplantation, rather than attributing the entire pattern to expected reperfusion injury.
Common pitfall: An early aminotransferase surge alone does not establish primary nonfunction. Conversely, progressive metabolic and synthetic failure should not be dismissed as routine postoperative injury.
OPTN Policies — Effective October 1, 2026 · EASL Clinical Practice Guidelines on Liver Transplantation — 2024
40.Why is early hepatic artery thrombosis a graft emergency?
After transplantation, the biliary tree depends critically on hepatic arterial perfusion. Early hepatic artery thrombosis can therefore cause severe graft injury, biliary ischemia and graft loss. An abrupt change in liver tests or graft function should prompt urgent Doppler assessment and confirmatory vascular evaluation when needed. Management is time sensitive and may involve revascularization or retransplantation. Demonstrating a vascular cause takes priority over assuming rejection and escalating immunosuppression without anatomic assessment.
Apply it
A recipient develops abrupt graft dysfunction several days after transplantation. Arrange immediate hepatic arterial flow assessment and transplant surgical review rather than beginning empirical rejection treatment before excluding a potentially reversible vascular catastrophe.
Common pitfall: Rejection is only one cause of early abnormal liver tests. Empirical steroids cannot restore arterial flow and may delay an intervention that preserves the graft.
EASL Clinical Practice Guidelines on Liver Transplantation — 2024 · OPTN Policies — Effective October 1, 2026
41.How should an HCV-uninfected liver recipient be managed after an HCV-viremic donor graft?
An HCV RNA-positive donor presents a substantial transmission risk regardless of antibody status. Use requires informed consent, access to antiviral treatment and structured follow-up. AASLD-IDSA guidance recommends early pangenotypic direct-acting antiviral treatment for an HCV-uninfected liver recipient once clinically stable, within the first two weeks and preferably the first week. Liver recipients require the recommended full treatment course; abbreviated approaches studied in other organ settings should not be assumed applicable to liver grafts.
Apply it
An HCV-uninfected patient receives a liver from an RNA-positive donor and is stable on postoperative day 5. Activate the agreed early antiviral plan rather than waiting for clinical hepatitis or transferring a shortened non-liver protocol to this recipient.
Common pitfall: Donor antibody status cannot override detectable donor RNA. Evidence from kidney transplantation does not automatically establish an appropriate antiviral duration for liver recipients.
Post-transplant20%
42.How is acute T cell-mediated rejection distinguished from other graft injuries?
Acute T cell-mediated rejection is a histologic diagnosis supported by features such as portal inflammation, bile duct injury and venous endotheliitis. Liver biochemical abnormalities are insufficiently specific because biliary obstruction, vascular injury, infection and drug toxicity can produce overlapping patterns. Evaluation should address these competing causes and use biopsy when appropriate before selecting rejection treatment. A low immunosuppressant level increases concern but does not independently prove that rejection explains the current graft dysfunction.
Apply it
A recipient with missed medication doses develops elevated aminotransferases and alkaline phosphatase. Check vascular and biliary causes and obtain appropriate biopsy evidence rather than treating the adherence history as proof that every abnormality represents cellular rejection.
Common pitfall: A low tacrolimus trough is a risk clue rather than a tissue diagnosis. Empirical treatment can obscure infection or delay correction of obstruction.
EASL Clinical Practice Guidelines on Liver Transplantation — 2024
43.What evidence is needed beyond donor-specific antibodies to diagnose antibody-mediated rejection?
Donor-specific HLA antibodies demonstrate sensitization but do not alone establish antibody-mediated graft injury. Diagnosis integrates graft dysfunction, compatible histology, antibody evidence, appropriate C4d findings and exclusion of alternative causes. The meaning of an antibody result therefore depends on the tissue and clinical context. Treating every positive assay as rejection risks unnecessary intensification of immunosuppression, while dismissing antibodies despite compatible injury can miss a clinically important mechanism requiring specialist assessment.
Apply it
A stable recipient has newly detected donor-specific antibodies but normal liver tests and no demonstrated tissue injury. Review the result and monitoring plan rather than diagnosing antibody-mediated rejection and initiating intensive treatment solely because the assay is positive.
Common pitfall: Sensitization and active rejection are different findings. Neither an antibody assay nor a single stain should replace integrated clinical and histologic assessment.
EASL Clinical Practice Guidelines on Liver Transplantation — 2024
44.Which features suggest chronic rejection in a cholestatic graft?
Chronic rejection can cause progressive cholestatic graft dysfunction through bile duct loss and vascular injury. Biopsy evidence of ductopenia must be interpreted alongside the clinical course and exclusion of biliary obstruction, vascular compromise, recurrent disease and drug-related injury. Poor immunosuppressant adherence can increase concern, but biochemical cholestasis is not specific. Early recognition matters because persistent structural damage may become difficult to reverse and can ultimately require retransplant consideration despite attempted optimization of immunosuppression.
Apply it
A recipient with prolonged medication interruptions develops progressive cholestasis. After assessing ducts and arterial flow, obtain biopsy evaluation for chronic rejection rather than assuming that the cholestatic pattern proves a mechanical biliary stricture.
Common pitfall: Cholestasis cannot distinguish ductopenic rejection from obstruction by itself. Increasing immunosuppression without evaluating anatomy can leave a treatable biliary or vascular cause unresolved.
EASL Clinical Practice Guidelines on Liver Transplantation — 2024
45.When should MRCP precede intervention for a post-transplant biliary stricture?
MRCP is useful when a post-transplant biliary stricture is suspected but diagnostic uncertainty remains, providing noninvasive ductal mapping. ERCP is generally the initial therapeutic approach when anatomy permits and an intervention is indicated. Infection risk increases when complete drainage cannot be ensured, supporting periprocedural antibiotics in that setting. The choice depends on the probability of obstruction, clinical urgency and anatomy; a patient requiring urgent drainage should not undergo noninvasive testing merely to postpone necessary treatment.
Apply it
A stable recipient has cholestatic tests and an equivocal ultrasound without clear ductal dilation. Use MRCP to clarify a suspected stricture; if subsequent intervention may leave segments undrained, plan appropriate antibiotic coverage with the endoscopic procedure.
Common pitfall: Absence of marked ductal dilation does not exclude a transplant stricture. Antibiotic planning should account for incomplete drainage rather than assuming every procedure provides source control.
ASGE Post-Liver Transplant Biliary Stricture Guideline — 2023
46.How does donor-recipient serostatus guide CMV prevention?
CMV donor-positive/recipient-negative liver recipients have the highest conventional serologic risk because they lack prior immunity. Adult prevention options include valganciclovir prophylaxis for three to six months or an organized preemptive strategy. Individualize prophylaxis duration to immunosuppression, tolerance and risk; adjust valganciclovir to kidney function and monitor blood counts. Preemptive care requires reliable scheduled CMV DNA testing, generally at least weekly during the surveillance period, rapid review and treatment access. Serostatus estimates risk and does not diagnose active disease.
Apply it
A donor-positive/recipient-negative recipient cannot reliably attend frequent laboratory visits. Resolve the access barrier and favor a feasible prevention strategy; an informal plan to test only when symptoms appear is not preemptive therapy.
Common pitfall: Underdosing prophylaxis without appropriate renal justification can compromise prevention. Positive IgG is prior exposure, not evidence of current tissue-invasive disease.
Fourth International Consensus Guidelines on CMV in Solid Organ Transplantation — 2025
47.Why can gastrointestinal CMV disease occur with a negative plasma test?
CMV can produce compartmentalized gastrointestinal tissue disease without readily detectable circulating DNA, particularly in some seropositive recipients. Persistent diarrhea, abdominal symptoms or gastrointestinal bleeding therefore warrant tissue-based evaluation when suspicion remains despite a negative plasma assay. Endoscopy with biopsy and appropriate histopathologic testing establishes invasive disease more directly. Blood viral-load testing is useful but does not replace assessment of the affected organ, and medication toxicity or other infections remain important alternative explanations.
Apply it
A recipient has persistent diarrhea and weight loss, but plasma CMV DNA is undetectable. If clinical suspicion remains, pursue endoscopy with biopsies while investigating other causes instead of excluding invasive CMV disease from the blood result alone.
Common pitfall: An undetectable plasma assay cannot universally rule out gastrointestinal CMV. Conversely, symptoms alone cannot distinguish CMV from mycophenolate toxicity or another intestinal disorder.
Fourth International Consensus Guidelines on CMV in Solid Organ Transplantation — 2025
48.How is recurrent PSC distinguished from other post-transplant biliary injury?
Recurrent PSC can produce multifocal biliary stricturing after transplantation, but similar cholangiographic appearances occur with hepatic arterial problems, ischemic cholangiopathy and other graft injuries. Diagnosis requires an appropriate history and timing together with exclusion of competing causes. The original PSC diagnosis increases suspicion but does not settle the cause of every new stricture. Arterial evaluation and assessment of the distribution and context of ductal injury help distinguish recurrence from technical or ischemic disease.
Apply it
A recipient transplanted for PSC develops multiple intrahepatic strictures. Review arterial patency, donor and preservation history, timing and other graft findings before assigning recurrence, because the same ductal pattern may reflect ischemic rather than recurrent inflammatory disease.
Common pitfall: A history of PSC does not make every postoperative stricture recurrent PSC. Missing an arterial cause can delay management of a potentially actionable problem.
EASL Clinical Practice Guidelines on Liver Transplantation — 2024
49.How should declining renal function alter post-transplant immunosuppression assessment?
Calcineurin inhibitors can contribute to renal dysfunction through vasoconstrictive and chronic toxic effects, but post-transplant kidney disease is often multifactorial. Evaluation should include drug exposure, interactions, blood pressure, diabetes, volume status and other renal causes. A renal-sparing strategy may reduce calcineurin inhibitor exposure while maintaining sufficient rejection protection through an individualized regimen. Abrupt withdrawal without a substitute plan is unsafe because improving one toxicity can introduce graft rejection and loss of overall transplant benefit.
Apply it
A recipient develops a rising creatinine after a new interacting medication raises tacrolimus exposure. Correct the interaction and reassess kidney function before labeling irreversible chronic nephropathy or abruptly stopping all calcineurin inhibitor therapy without a replacement strategy.
Common pitfall: Not every creatinine rise is chronic tacrolimus damage. Conversely, a therapeutic trough does not exclude all drug contribution or justify ignoring other renal risks.
EASL Clinical Practice Guidelines on Liver Transplantation — 2024 · PROGRAF Prescribing Information
50.Why does cardiovascular prevention remain central after a successful liver transplant?
Successful transplantation corrects liver failure but does not remove obesity, diabetes, hypertension, dyslipidemia or the cardiovascular risks associated with prior metabolic disease. Immunosuppressive therapy can further aggravate metabolic risk. Follow-up should therefore integrate blood pressure, glucose, lipids, activity, nutrition and smoking assessment alongside graft tests. Recurrent or new graft steatosis is part of this systemic risk picture, and normal aminotransferases should not distract from prevention of cardiovascular and renal complications.
Apply it
A recipient has normal liver tests but gains substantial weight and develops hypertension and diabetes. Address cardiovascular risk and metabolic treatment proactively rather than considering follow-up satisfactory because the graft's biochemical profile remains normal at clinic visits.
Common pitfall: Normal graft tests do not establish overall transplant health. Focusing exclusively on rejection surveillance can miss preventable cardiovascular disease and progressive metabolic complications.
EASL Clinical Practice Guidelines on Liver Transplantation — 2024 · EASL-EASD-EASO MASLD Clinical Practice Guidelines — 2024
51.How should immunosuppressed recipients reduce skin-cancer risk?
Chronic immunosuppression increases susceptibility to malignancy, including skin cancer, by impairing immune surveillance. Prevention includes limiting ultraviolet exposure, protective clothing, sunscreen and appropriate skin examination, with prompt evaluation of changing lesions. The CELLCEPT prescribing information specifically emphasizes sun-exposure precautions. Cancer prevention belongs in routine maintenance even when the graft is stable. A new suspicious lesion requires assessment rather than reassurance based on young age, a modest drug dose or the absence of previous cancer.
Apply it
A stable recipient who works outdoors asks whether cancer precautions remain necessary years after transplantation. Reinforce sun protection and skin surveillance, and arrange evaluation of a newly enlarging scaly lesion rather than waiting for the next annual graft review.
Common pitfall: Long-term graft stability does not remove immunosuppression-associated malignancy risk. Sunscreen alone also does not replace protective behavior or assessment of suspicious lesions.
CELLCEPT Prescribing Information · EASL Clinical Practice Guidelines on Liver Transplantation — 2024
52.Why must mycophenolate be reviewed before pregnancy after transplantation?
Mycophenolate increases pregnancy-loss and congenital-malformation risk. Establish a suitable alternative regimen before conception while confirming graft stability. Under the CELLCEPT label, females of reproductive potential need acceptable contraception throughout treatment and for six weeks after stopping, unless choosing abstinence. Oral contraceptive pills require an additional barrier method because CELLCEPT can reduce their effectiveness. Review renal function, comorbidities and the entire regimen; the label's minimum contraception interval does not replace individualized assessment of readiness for pregnancy.
Apply it
A recipient plans a supervised switch from mycophenolate. Maintain acceptable contraception through the transition and for six weeks after the final dose, then reassess whether the alternative regimen and graft are stable before conception.
Common pitfall: Contraception does not end on the day mycophenolate stops. Abruptly stopping all immunosuppression can precipitate rejection without creating a safe pregnancy plan.
CELLCEPT Prescribing Information · EASL Clinical Practice Guidelines on Liver Transplantation — 2024
53.Which findings increase concern for post-transplant lymphoproliferative disorder?
Most PTLD cases described in the CELLCEPT label are associated with Epstein-Barr virus, and risk is greatest in EBV-seronegative recipients. Overall immunosuppressive intensity and duration matter more than attributing malignancy risk to one agent. This makes a previously EBV-seronegative recipient exposed to intensified immunosuppression a particularly concerning risk profile. Incorporate that risk into infection and malignancy surveillance and the review of cumulative immunosuppression. A risk profile supports investigation and prevention planning; it does not itself establish PTLD or justify unmonitored withdrawal.
Apply it
Compare two otherwise similar recipients: one was EBV-seronegative and recently required intensified rejection therapy; the other was EBV-seropositive with low maintenance exposure. Prioritize the first for a focused PTLD-risk review and a clearly documented surveillance plan.
Common pitfall: CMV serostatus does not substitute for EBV risk assessment. Switching one immunosuppressant without considering total exposure does not eliminate PTLD risk.
Transplant Immunology6%
54.How does tacrolimus suppress T-cell activation?
Tacrolimus binds the intracellular immunophilin FKBP-12, and the resulting complex inhibits calcineurin. This prevents activation of nuclear factor of activated T cells and reduces transcription of interleukin-2 and other signals needed for T-cell activation. The mechanism differs from blocking nucleotide synthesis or inhibiting mTOR-mediated proliferation. Recognizing the target helps explain why tacrolimus is combined with mechanistically different agents and why dose adjustment must consider both rejection protection and exposure-related toxicity.
Apply it
A recipient takes tacrolimus with mycophenolate. Explain that the drugs act at different stages of lymphocyte activation and proliferation, so the combination can support immunosuppression without assuming that their mechanisms or adverse-effect profiles are interchangeable.
Common pitfall: Tacrolimus and sirolimus both bind FKBP proteins but inhibit different downstream targets. A shared binding partner does not make their clinical mechanisms identical.
55.Why can a CYP3A inhibitor abruptly increase tacrolimus toxicity?
Tacrolimus exposure is strongly affected by CYP3A-mediated metabolism. Strong CYP3A inhibitors, including selected azole antifungals and macrolides, can sharply raise concentrations, causing nephrotoxicity, neurotoxicity and other adverse effects. Starting or stopping an interacting drug requires coordinated dose management and close concentration monitoring. An unchanged prescribed tacrolimus dose does not imply unchanged exposure, and monitoring must continue when the inhibitor is withdrawn because exposure can then fall and threaten rejection protection.
Apply it
A recipient develops tremor and rising creatinine after starting a strong azole inhibitor. Check tacrolimus exposure and coordinate immediate interaction management rather than attributing the symptoms solely to a new infection or increasing immunosuppression for presumed rejection.
Common pitfall: Medication reconciliation must include newly started and recently stopped drugs. Correcting an interaction also requires follow-up when the inhibitor's effect diminishes.
56.How does mycophenolate preferentially inhibit lymphocyte proliferation?
Mycophenolate mofetil is converted to mycophenolic acid, which inhibits inosine monophosphate dehydrogenase and reduces de novo guanine nucleotide synthesis. Lymphocytes depend heavily on this pathway during proliferation, making them particularly susceptible to its effects. This mechanism complements calcineurin inhibition rather than duplicating it. Gastrointestinal toxicity and cytopenias can complicate treatment, so new diarrhea or low blood counts warrant evaluation of both medication effects and competing infectious or hematologic causes before regimen changes.
Apply it
A recipient taking mycophenolate develops diarrhea and leukopenia. Recognize a plausible drug-related pattern, but evaluate infection and other causes before reducing therapy, because an incorrect attribution may either prolong toxicity or unnecessarily weaken rejection protection.
Common pitfall: Mycophenolate does not inhibit calcineurin. Its plausible adverse effects also do not establish that every episode of post-transplant diarrhea is medication-induced.
57.How does everolimus differ from a calcineurin inhibitor, and which toxicities affect selection?
Everolimus binds FKBP-12; the complex inhibits mTOR-dependent signaling and lymphocyte proliferation downstream of growth-factor stimulation. It can support reduced tacrolimus exposure but introduces proteinuria, dyslipidemia, delayed wound healing, fluid accumulation and noninfectious pneumonitis risks. The ZORTRESS label specifies starting no earlier than 30 days after liver transplantation because early hepatic artery thrombosis has been associated with mTOR inhibitors. Use with reduced tacrolimus and therapeutic monitoring rather than assuming complete calcineurin-inhibitor elimination is equivalent.
Apply it
A recipient with renal dysfunction also has substantial proteinuria and a poorly healing wound. These findings argue against an automatic everolimus substitution; compare its specific risks with the proposed reduction in tacrolimus exposure.
Common pitfall: A renal-sparing aim does not make everolimus free of renal or surgical toxicity. Existing proteinuria and wound complications can materially change the choice.
Ethics and Regulatory Issues5%
58.How should a living donor's confidential withdrawal be protected?
Living donation requires voluntary, informed participation without coercion. A donor may withdraw, and information about the reasons should remain confidential unless the donor authorizes disclosure. The team can communicate that donation will not proceed without revealing private medical or personal details. Recipient need does not override donor autonomy. Independent donor support and careful communication help protect the donor from pressure while allowing the recipient's team to pursue other treatment or donor options.
Apply it
A potential donor privately says that family pressure influenced the decision and asks to stop without explaining why to the recipient. Support withdrawal, preserve the stated confidentiality and coordinate an appropriate neutral communication about the donation not proceeding.
Common pitfall: Requiring the donor to justify withdrawal to the recipient undermines voluntariness. Recipient urgency does not create entitlement to another person's confidential information or donation.
HRSA/OPTN Guidance for Donor and Recipient Information Sharing
59.How does adult laboratory MELD differ from standardized HPS exception qualification?
Under the October 1, 2026 OPTN policies, candidates at least 18 years old at registration use the adult MELD calculation incorporating bilirubin, INR, creatinine, sodium, albumin and sex. An exception requires separate qualifying evidence. HPS Policy 9.5.E requires ascites, varices, splenomegaly or thrombocytopenia; a shunt demonstrated by contrast echocardiography or lung scan; room-air PaO2 below 60 mmHg measured within 30 days before the initial request; and no clinically significant primary pulmonary disease. Clinical HPS diagnosis alone does not establish this standardized exception.
Apply it
A candidate registered at age 52 has varices, contrast-echo shunting, no significant primary lung disease and room-air PaO2 55 mmHg measured 12 days before the request. These findings satisfy the listed HPS evidence elements. PaO2 62 mmHg would not meet the exception oxygen threshold, even if clinical HPS were present.
Common pitfall: Current age alone does not replace the specified registration-age condition. Hypoxemia on supplemental oxygen or an outdated room-air measurement does not supply the required initial evidence.
60.How should structural barriers be distinguished from unwillingness to adhere?
Psychosocial assessment should identify why essential care has been missed before concluding that a candidate is unwilling to follow treatment. Language barriers, limited health literacy, transportation, medication cost and unstable access can produce apparent nonadherence. A fair assessment evaluates understanding, resources and the response to practical support, while still addressing genuine safety risks. Documenting barriers and feasible interventions improves the accuracy of candidacy decisions and avoids treating social disadvantage as a fixed personal trait.
Apply it
A candidate repeatedly misses laboratory visits because the available bus route cannot reach the center before work. Explore local testing, scheduling and transport support, then reassess follow-through rather than recording the pattern immediately as refusal of care.
Common pitfall: Supportive assessment does not mean ignoring adherence risks. It means distinguishing remediable access problems from persistent behavior after understanding and feasible access have been established.
EASL Clinical Practice Guidelines on Liver Transplantation — 2024 · Transplant Hepatology Certification Blueprint — January 2026
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Spend the largest share of study time on advanced hepatology and pretransplant decisions, including tumor biology, renal recovery potential and pulmonary vascular risk.
- Practise urgent discrimination: Wilson-associated liver failure, infected obstructed bile ducts, high-risk variceal bleeding, early arterial thrombosis and catastrophic graft failure.
- Connect each abnormal graft pattern to vascular, biliary, immune, infectious, recurrent-disease and drug-related alternatives before choosing treatment.
- Interpret test boundaries explicitly: ceruloplasmin, HCV antibody, ascitic neutrophils, LI-RADS categories, CMV blood assays and donor-specific antibodies answer different questions.
- Assess prognosis through biochemical response, tumor behavior, organ-failure trajectories, frailty and cumulative immunosuppressive exposure.
- Integrate nutrition, addiction treatment, vaccination, bone health, reproductive planning, malignancy prevention and access barriers into longitudinal care.
- Use current US OPTN policy for donor exclusions, simultaneous liver-kidney allocation and exceptions; distinguish policy eligibility from clinical diagnosis.
A practical preparation plan
1. Map the full initial certification outline
Read the January 2026 expanded CERT outline and identify HIGH and MEDIUM topic-task combinations. Use the five clinical-domain weights to plan study time, then add topics beyond these 60 selected concepts to complete the official scope.
2. Build decision pathways around clinical triggers
For each syndrome, write the decisive finding, the next test or treatment and the dangerous alternative. Include HRS-AKI criteria, pulmonary hemodynamics, tumor staging and the chronicity required for liver-kidney allocation.
3. Practise calculations and qualifying criteria
Calculate ascitic neutrophils, albumin gradients, paracentesis albumin replacement and donor remnant percentages. Work through HPS exception evidence and distinguish a clinical diagnosis from allocation qualification.
4. Compare risk and prognosis
Explain how persistent cholestatic biochemistry, AFP response, frailty, worsening organ failure and EBV susceptibility change expected outcomes and management. Separate a risk marker from proof of active disease.
5. Review every answer option
Complete the 20 drills without references, then explain why the correct option fits and why each competing approach fails in the specific case. Identify errors in clinical interpretation, arithmetic, timing or applicability.
6. Close gaps against the official scope
Return to the expanded outline after review. Add focused study of remaining genetic disorders, pregnancy-related liver disease, less common tumors, PTLD diagnosis and treatment, and the complete vaccination and bone-health recommendations.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABIM Assessment Blueprints
- Transplant Hepatology Certification Blueprint — January 2026
- Transplant Hepatology Certification Examination — Expanded Blueprint
- ABIM Expanded Blueprints
- ABIM Transplant Hepatology Certification Policies
- AASLD 2022 Practice Guidance on Wilson Disease
- EASL Clinical Practice Guidelines on Autoimmune Hepatitis — 2025
- AASLD Primary Biliary Cholangitis Practice Guidance — 2018
- AASLD Primary Biliary Cholangitis Guidance Index
- AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma
- AASLD Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome Practice Guidance — 2021
- Baveno VII — Renewing Consensus in Portal Hypertension
- ACR LI-RADS Current Releases
- ACR CT/MRI LI-RADS v2018 Core
- AASLD: Defining and Managing Acute Liver Failure
- AASLD Alcohol-Associated Liver Disease Practice Guidance — 2019
- AASLD: Evolution of the Six-Month Sobriety Rule
- EASL-EASD-EASO MASLD Clinical Practice Guidelines — 2024
- AASLD Malnutrition, Frailty and Sarcopenia Practice Guidance — 2021
- EASL Clinical Practice Guidelines on Liver Transplantation — 2024
- Hypothermic Machine Perfusion in Liver Transplantation — A Randomized Trial
- AASLD-IDSA HCV Guidance: Organs from HCV-Viremic Donors
- OPTN Policies — Effective October 1, 2026
- ASGE Post-Liver Transplant Biliary Stricture Guideline — 2023
- Fourth International Consensus Guidelines on CMV in Solid Organ Transplantation — 2025
- CELLCEPT Prescribing Information
- PROGRAF Prescribing Information
- HRSA/OPTN Guidance for Donor and Recipient Information Sharing
- nihms-1991444.pdf
- zortress.pdf
- Acute%20Liver%20Failure%20Update2011.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.